Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world
Background HIV–HCV coinfection produces high morbi-mortality. Direct-acting antivirals (DAAs) have shown high efficacy, although special attention should be paid to the risk of drug interactions. However, due to the lack of representativeness of coinfected patients in clinical trials, it is important to know real-world results. Objective To evaluate DAA treatment effectiveness in coinfected patients. We also analyse safety profile of DAA treatment and drug interactions between HCV and HIV therapy. Setting Descriptive study carried in a tertiary hospital of Spain Method HIV–HCV coinfected patients treated with DAAs between November 2014 and June 2016 were included. Main outcome measure Efficacy was measured in terms of sustained virologic response at week 12 after the end of therapy. Adverse events that led to treatment discontinuation were registered to evaluate the safety profile, and also drug interactions between DAAs and antiretroviral treatment were evaluated. Results Main HCV genotypes were 1a (34.9%) and 4 (24.5%). 51.9% were HCV previously treated, 54.7% had grade 4 liver fibrosis. SVR12 was reported in 90.6%. HCV treatment was well tolerated and there were no discontinuations because of adverse events. 30.2% of HIV treatments had to be modified before DAA treatment was started due to interactions, HIV suppression was not compromised. Conclusion DAA treatment in coinfected patients seems to be highly effective and secure. Evaluation of drug interactions must be a priority in order to maximize effectiveness and avoid toxicity.
KeywordsAntiretroviral therapy Direct-acting antivirals Drug-drug interactions HIV-HCV Coinfection Sustained virologic response
This study did not receive special funding.
Conflicts of interest
All the authors declare that they have no conflict of interest.
- 2.WHO. Fact sheet hepatitis C 2015. World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/es/. Accessed 9 Feb 2017.
- 4.Crespo M, Von Wichmann MA. Manejo de las hepatitis virales en pacientes infectados por el VIH. Guía de Práctica Clínica de GeSIDA. http://gesida-seimc.org/category/guias-clinicas/otras-guias-vigentes/page/2/. Accessed 9 Feb 2017.
- 5.Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, et al. CIHR Canadian HIV trials network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol. 2013;24:217–38.PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Berenguer J, Álvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–13.CrossRefPubMedGoogle Scholar
- 10.Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55:728–36.CrossRefPubMedGoogle Scholar
- 24.University of Liverpool. HEP drug interactions. http://www.hep-druginteractions.org/. Accessed 10 Feb 2017.
- 25.Lexicomp. http://online.lexi.com/lco/action/interact. Accessed 10 Feb 2017.
- 26.Agencia Española de Medicamentos y Productos Sanitarios—Ministerio de Sanidad Servicios Sociales e Igualdad. http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar. Accessed 10 Feb 2017.
- 29.AEEH y SEIMC. Documento del III Consenso español sobre tratamiento de la hepatitis C. 2016. http://www.seimc.org/grupodeestudio.php?Grupo=GEHEP&mn_Grupoid=14&mn_MP=512&mn_MS=513. Accessed 10 Feb 2017.
- 30.Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, et al. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics. Open Forum Infect Dis. 2016;3(2):ofw059. https://doi.org/10.1093/ofid/ofw059.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Zhang J, Nguyen D, Hu K-Q. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci. (Boston). 2016;9:47–54.Google Scholar
- 34.Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.CrossRefPubMedGoogle Scholar